ABOUT US

Dr. Brian Salmons is the CEO & President and one of the founders of the company.
He has had 25 years experience in biotech, which commenced with him being appointed the Scientific Director of Bavarian Nordic (BN). He co-founded Austrianova Biotechnology GmbH in 2001 as well as Austrianova in 2007, where he also became the CEO.
Past experiences include being directly responsible for the initial Phase I/II clinical trials of an encapsulated cell product in pancreatic cancer in humans and mammary (breast) cancer in dogs as well as being part of the team that took Bavarian Nordic to its IPO in 1998. He has also been an advisor/consultant for a number of Biotech companies.
Before moving to the commercial world in 1994, he spent 10 in years in academia.

Prof. Walter H. Günzburg, Ph.D. is the Chairman and one of the founders of the company.
He is also Professor of Virology at the University of Veterinary Medicine, Vienna, Austria and formerly an Adjunct Professor at the National University of Singapore. He was a founder, board member and former Chairman of Virusure GmbH, a virus testing company located in Vienna, Austria that has recently been acquired by Asahi-Kasei and has also been an advisor to Paktis (Germany) and Tocagen (USA).
He has also served as a member of German Federal Medical Association Ethics Committee for Gene Therapy (Kommission Somatische Gentherapie der Bundesärztekammer) since 1997 as well as the European Academy for the Study of Consequences of Scientific and Technological Advances (since 1998).
Prof. Günzburg has 40 years experience in virology, and 25 years experience in cell therapy and bioencapsulation. He has published numerous peer reviewed scientific publications.

Rahul is a third-generation Thai of Indian origin. He finished secondary school in Bangkok and moved to Australia to complete his Bachelor degree in Biomedicine with Honours from the University of Melbourne. Rahul spent his honours year researching at the prestigious Peter MacCallum Cancer Centre under the supervision of Dr. Mark Shackleton. He then moved back to Bangkok as the first employee of the newly founded Austrianova Thailand. Rahul has been with Austrianova Thailand for the past 7 years and is currently the Chief Production Officer of the company. In 2018, Rahul was awarded the TIYAA STEM award for his work in overseeing the manufacturing of the first cell therapy in Thailand; a treatment for pancreatic cancer that will be going into phase 2 clinical trials in the US in 2020. Through his work at Austrianova, Rahul is well very connected with the biotech and pharma landscape of Thailand.

Pierre, who is based in Singapore, holds an MBA from ESSEC Business School (France) and a Masters in Economics from Universite Paris-II Assas (France). He formerly held positions with PWC as well as leading the investment research teams for Tokio Marine Asset Management and Deutsche Bank Asset & Wealth Management. He was also a former investment analyst with Aberdeen Asset Management and BNP Paribas Fortis.